Heinze Georg, Kainz Alexander, Hörl Walter H, Oberbauer Rainer
Core Unit of Medical Statistics and Informatics, Medical University of Vienna, 1090 Vienna, Austria.
BMJ. 2009 Oct 23;339:b4018. doi: 10.1136/bmj.b4018.
To determine the optimal range of increase in haemoglobin concentration with treatment with erythropoietins that is safe and is not associated with mortality.
Retrospective cohort study. The analysis was adjusted for several covariables with Cox regression analysis with spline functions. Use of erythropoietins, haemoglobin concentration, and covariables were included in a time varying manner; variable selection was based on the purposeful selection algorithm.
Transplantation centres in Austria.
1794 renal transplant recipients recorded in the Austrian Dialysis and Transplant Registry who received a transplant between 1 January 1992 and 31 December 2004 and survived at least three months.
Survival time and haemoglobin concentration after treatment with erythropoietins.
The prevalence of use of erythropoietins has increased over the past 15 years to 25%. Unadjusted extended Kaplan-Meier analysis suggests higher mortality in patients treated with erythropoietins, in whom 10 year survival was 57% compared with 78% in those not treated with erythropoietins (P<0.001). In the treated patients there were 5.4 events/100 person years, compared with 2.6 events/100 person years in those not treated (P<0.001). After adjustment for confounding by indication, comorbidities, comedication, and laboratory readings, haemoglobin concentrations >125 g/l were associated with increased mortality in treated patients (hazard ratio 2.8 (95% confidence interval 1.0 to 7.9) for haemoglobin concentration 140 g/l v 125 g/l), but not in those not treated (0.7, 0.4 to 1.5). When haemoglobin concentrations were 147 g/l or above, patients treated with erythropoietins showed significantly higher mortality than those who were not treated (3.0, 1.0 to 9.4).
Increasing haemoglobin concentrations to above 125 g/l with erythropoietins in renal transplant recipients is associated with an increase in mortality. This increase was significant at concentrations above 140 g/l.
确定使用促红细胞生成素治疗时血红蛋白浓度升高的最佳范围,该范围应是安全的且与死亡率无关。
回顾性队列研究。采用带样条函数的Cox回归分析对多个协变量进行校正。促红细胞生成素的使用、血红蛋白浓度及协变量按时间变化方式纳入;变量选择基于有目的选择算法。
奥地利的移植中心。
奥地利透析与移植登记处记录的1794例肾移植受者,这些患者于1992年1月1日至2004年12月31日期间接受移植且存活至少3个月。
促红细胞生成素治疗后的生存时间和血红蛋白浓度。
在过去15年中,促红细胞生成素的使用比例已增至25%。未经校正的扩展Kaplan-Meier分析表明,接受促红细胞生成素治疗的患者死亡率更高,其10年生存率为57%,而未接受促红细胞生成素治疗的患者为78%(P<0.001)。接受治疗的患者每100人年有5.4例事件发生,而未接受治疗的患者为每100人年2.6例事件(P<0.001)。在对适应证、合并症、合并用药及实验室检查结果进行混杂因素校正后,血红蛋白浓度>125 g/l与接受治疗患者的死亡率增加相关(血红蛋白浓度140 g/l与125 g/l相比,风险比为2.8(95%置信区间1.0至7.9)),但在未接受治疗的患者中则不然(0.7,0.4至1.5)。当血红蛋白浓度达到或高于147 g/l时,接受促红细胞生成素治疗的患者死亡率显著高于未接受治疗的患者(3.0,1.0至9.4)。
肾移植受者使用促红细胞生成素使血红蛋白浓度升高至125 g/l以上与死亡率增加相关。在浓度高于140 g/l时,这种增加具有显著性。